Study guide
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy
Key Takeaways Explain This Topic AI
Autologous HSCT relies on high-dose chemotherapy followed by patient stem cell rescue (common in Multiple Myeloma and relapsed Lymphoma), whereas Allogeneic HSCT relies on donor stem cells to establish a Graft-versus-Leukemia (GVL) immune effect.
Mobilization of peripheral blood stem cells is achieved using G-CSF (filgrastim) alone or combined with plerixafor (CXCR4 antagonist) to achieve a minimum target yield of 2.0 x 10^6 CD34+ cells/kg.
Sinusoidal Obstruction Syndrome (SOS/VOD) is an early post-transplant hepatic toxicity presenting with jaundice, painful hepatomegaly, and fluid retention within 21 days, treated specifically with defibrotide.
Acute Graft-versus-Host Disease (aGVHD) occurs within 100 days post-allogeneic HSCT, primarily targeting skin (maculopapular rash), GI tract (voluminous watery green diarrhea), and liver (hyperbilirubinemia); first-line treatment is high-dose IV methylprednisolone (2 mg/kg/day).
CAR T-cell therapy utilizes genetically engineered autologous T cells targeting specific antigens (CD19, BCMA), with major toxicities of Cytokine Release Syndrome (CRS, treated with tocilizumab) and ICANS (treated with dexamethasone).
Last updated: August 2026
Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy
Hematopoietic Stem Cell Transplantation (HSCT) and adoptive cellular therapies represent curative or life-prolonging modalities for hematologic malignancies and select non-malignant disorders. As the clinical indications expand and novel cellular products enter clinical practice, Oncology Nurse Practitioners (APRNs) play a pivotal role in pre-transplant evaluation, conditioning toxicity management, acute and chronic Graft-versus-Host Disease (GVHD) diagnosis, and cellular therapy toxicity mitigation.
- 1. Classifications, Donor Sources & Mobilization
- Classifications of HSCT
Autologous HSCT : Stem cells are collected from the patient, cryopreserved, and reinfused following high-dose myeloablative chemotherapy. Operates solely on the principle of high-dose chemo intensity; stem cells act as a hematopoietic rescue. Main indications: Multiple Myeloma, relapsed Hodgkin and non-Hodgkin Lymphoma.
Allogeneic HSCT : Stem cells are harvested from a healthy donor (human leukocyte antigen [HLA]-matched sibling, matched unrelated donor [MUD], haploidentical family member, or umbilical cord blood). Operates on both chemotherapy conditioning and the immunological Graft-versus-Leukemia (GVL) effect, where donor immune cells eradicate residual recipient tumor cells. Main indications: Acute Leukemias (AML, ALL), Myelodysplastic Syndromes (MDS), Severe Aplastic Anemia.
Syngeneic HSCT : Stem cells harvested from an identical twin (no GVHD, but no GVL effect).
Stem Cell Sources & Mobilization Protocols
Peripheral Blood Stem Cells (PBSC) : Most common source ( > 90 % >90\% > 90% ). Mobilized from bone marrow into peripheral blood using daily G-CSF (filgrastim 10 mcg/kg/day) ± \pm ± plerixafor (a CXCR4 chemokine receptor antagonist that releases stem cells bound to marrow stroma). Harvested via leukapheresis. Minimum target yield: ≥ 2.0 × 10 6 CD34 + cells/kg \ge 2.0 \times 10^6\text{ CD34}^+\text{ cells/kg} ≥ 2.0 × 1 0 6 CD34 + cells/kg .
Bone Marrow (BM) : Harvested via multiple iliac crest aspirations under general anesthesia. Associated with lower risk of chronic GVHD compared to PBSC.
Umbilical Cord Blood : Rich in primitive stem cells; requires less stringent HLA matching, but associated with delayed engraftment.
- 2. Conditioning Regimens & Early Post-Transplant Complications
- Conditioning Intensity
Myeloablative Conditioning (MAC) : High doses of chemotherapy ± \pm ± Total Body Irradiation (TBI) (e.g., Busulfan/Cyclophosphamide, TBI/Etoposide) designed to completely eradicate host marrow and provide maximal immunosuppression. Causes irreversible marrow aplasia without stem cell rescue.
Reduced-Intensity Conditioning (RIC) / Non-Myeloablative (NMA) : Uses lower chemotherapy doses to suppress host immunity sufficiently to permit donor stem cell engraftment, relying primarily on GVL for disease control. Preferred in older or comorbid patients.
Early Complications (Days 0 to +30)
Complication Pathophysiology & Clinical Triad APRN First-Line Management
Sinusoidal Obstruction Syndrome (SOS / VOD) Conditioning damage to hepatic sinusoidal endothelial cells leading to microvascular occlusion. Triad: Jaundice (elevated bilirubin), painful hepatomegaly, and fluid weight gain/ascites within 21 days post-HSCT. Defibrotide (6.25 mg/kg IV q6h), strict fluid restriction, daily weights, abdominal ultrasound with Doppler flows.
Engraftment Syndrome Massive neutrophil recovery releasing pro-inflammatory cytokines. Triad: Non-infectious fever, diffuse maculopapular rash, pulmonary capillary leak/hypoxia. Systemic corticosteroids ( Methylprednisolone 1–2 mg/kg/day IV ).
Idiopathic Pneumonia Syndrome (IPS) Non-infectious diffuse lung injury post-conditioning. Symptoms: Fever, dry cough, dyspnea, bilateral hypoxia. High-dose corticosteroids ± \pm ± etanercept.
TA-GVHD Transfused donor lymphocytes attack un-engrafted recipient tissues. Uniformly fatal. Mandatory prevention : Irradiation (25 Gy) of all cellular blood products.
3. Acute vs. Chronic Graft-versus-Host Disease (GVHD)
GVHD occurs when immunocompetent donor T lymphocytes recognize recipient histocompatibility antigens as foreign, initiating an immunological attack against host tissues. Donor T-Cell Activation (Allogeneic Graft)
- │
- ├── Onset < 100 Days: Acute GVHD (Inflammatory T-cell storm)
- │ ├── Target 1: Skin (Maculopapular rash -> Erythroderma)
- │ ├── Target 2: GI Tract (Watery green diarrhea > 500-1500 mL/day)
- │ └── Target 3: Liver (Cholestatic jaundice, elevated bilirubin)
- │
- └── Onset > 100 Days: Chronic GVHD (Fibrotic / Autoimmune-like)
- ├── Target 1: Skin (Scleroderma, lichen planus-like changes)
- ├── Target 2: Eyes / Mouth (Sicca syndrome, severe dry mouth/eyes)
- └── Target 3: Lungs (Bronchiolitis Obliterans Syndrome [BOS])
- Acute GVHD (aGVHD)
Timeline : Typically presents within 100 days post-transplant (peak onset days +20 to +50).
Organ Manifestations & Staging :
Skin : Maculopapular rash starting on palms, soles, head, and neck. Stage 1 ( < 25 % BSA <25\%\text{ BSA} < 25% BSA ) to Stage 4 (generalized erythroderma with bullae and desquamation).
Gastrointestinal : Secretory, voluminous green watery diarrhea ( > 500 mL/day >500\text{ mL/day} > 500 mL/day to > 1 , 500 mL/day >1,500\text{ mL/day} > 1 , 500 mL/day ), severe abdominal cramping, ileus, hematochezia.
Liver : Cholestatic jaundice with conjugated hyperbilirubinemia and elevated alkaline phosphatase.
First-Line Treatment : High-dose systemic corticosteroids: Methylprednisolone 2 mg/kg/day IV (divided BID). Continue until response, then slow taper.
Steroid-Refractory aGVHD : Defined as progression after 3 days or lack of response after 7 days of steroids. First-line FDA-approved second-line agent: Ruxolitinib (selective JAK1/JAK2 inhibitor, 10 mg PO BID).
Chronic GVHD (cGVHD)
Timeline : Manifests > 100 >100 > 100 days post-transplant (or classic overlap features).
Clinical Features : Resembles autoimmune connective tissue diseases. Sclerodermatous skin thickening, poikiloderma, severe dry eyes/mouth (sicca syndrome), oral lichen planus, esophageal web strictures, vaginal stenosis, and Bronchiolitis Obliterans Syndrome (BOS) (progressive obstructive airway disease with dry cough and dyspnea).
Management : Systemic corticosteroids ± \pm ± FDA-approved agents: Ruxolitinib , Belumosudil (ROCK2 inhibitor), or Ibrutinib (BTK inhibitor).
4. CAR T-Cell & Adoptive Cellular Therapies
Chimeric Antigen Receptor (CAR) T-cell therapy involves harvesting autologous T cells, genetically engineering them via viral vectors to express a synthetic receptor targeting tumor antigens (e.g., anti-CD19 in DLBCL/ALL; anti-BCMA in Multiple Myeloma), expanding them ex vivo , and reinfusing them following lymphodepleting chemotherapy (fludarabine/cyclophosphamide).
Major Toxicities & APRN Management
Cytokine Release Syndrome (CRS) :
Pathophysiology : Massive immune activation releasing high levels of IL-6, IFN-gamma, and TNF-alpha.
Symptoms : High fever ( > 38.0 ∘ C >38.0^\circ\text{C} > 38. 0 ∘ C ), hypotension, hypoxia, tachypnea, organ dysfunction.
Grading & Management :
Grade 1 (Fever only): Supportive care, antipyretics, workup for infection.
Grade 2 (Hypotension responsive to fluids; low-flow oxygen ≤ 6 L \le 6\text{L} ≤ 6 L ): Tocilizumab 8 mg/kg IV (IL-6 receptor antagonist; repeat q8h up to 4 doses total).
Grade 3–4 (Hypotension requiring vasopressors; high-flow oxygen/mechanical ventilation): Tocilizumab + High-dose Dexamethasone 10–20 mg IV q6h .
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) :
Symptoms : Impaired handwriting (dysgraphia - early sensitive sign), expressive aphasia, confusion, lethargy, tremors, seizures, cerebral edema.
Assessment : Administer ICE (Immune Effector Cell Encephalopathy) score shiftly.
Management : Tocilizumab does NOT cross the blood-brain barrier and is ineffective for isolated ICANS. Treat ICANS primarily with Dexamethasone 10–20 mg IV q6h (or methylprednisolone 1,000 mg/day IV for severe cerebral edema).